Erschienen in:
27.02.2018 | Onkologie | editorial
Revival of anti-angiogenic therapies in cancer
News from an old therapeutic concept—part 2
Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2018
Einloggen, um Zugang zu erhaltenExcerpt
Referring to the last issue presenting state of the art reviews [ 1] on the use of anti-angiogenic drugs in colorectal [ 2], urological [ 3, 4] and breast cancer [ 5] as well as in angiosarcomas [ 6], the present issue extends the topic to additional angiogenesis-dependent malignancies. Hereby, ovarian cancer and non-small cell lung cancer (NSCLC) represent two highly vascularized tumor entities where anti-angiogenic therapies form a robust backbone for the treatment of advanced stage disease mostly in combination with chemotherapy or newer therapeutic therapies. …Anzeige